pLv-HSA-uDys/eGFP Citations (2)

Originally described in: Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.
Kimura E, Han JJ, Li S, Fall B, Ra J, Haraguchi M, Tapscott SJ, Chamberlain JS Hum Mol Genet. 2008 Aug 15. 17(16):2507-17. PubMed Journal

---

Articles Citing pLv-HSA-uDys/eGFP

Articles
Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery. Hersh J, Condor Capcha JM, Iansen Irion C, Lambert G, Noguera M, Singh M, Kaur A, Dikici E, Jimenez JJ, Shehadeh LA, Daunert S, Deo SK. Pharmaceutics. 2021 Dec 15;13(12). pii: pharmaceutics13122159. doi: 10.3390/pharmaceutics13122159. PubMed
Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease. Eren SA, Tastan C, Karadeniz KB, Turan RD, Cakirsoy D, Kancagi DD, Yilmaz SU, Oztatlici M, Oztatlici H, Ozer S, Tumentemur G, Baykal AT, Ovali E. Curr Gene Ther. 2023;23(4):304-315. doi: 10.2174/1566523223666230407091317. PubMed

If you have published an article using this material, please email us at to have your article added to this page.